Financial Review for first quarter ended 30 June 2013 Revenue:   Total product revenue for the quarter ended 30 June 2013 decreased by  6% to US$65.0 million from US$69.0 million recorded in the previous  year's corresponding quarter. Total interventional cardiology revenues  decreased by 7% to US$60.9 million in the quarter ended 30 June 2013  from the US$65.7 million reported in the previous year's corresponding  quarter due to a drop in the Group's drug-eluting stents ("DES") sales  mainly as a result of the Group's efforts in reducing distributor  channel inventories in China in anticipation of China new tenders  pricing taking effect. The Group continues to see strong, double~djgit  sales growth in EMEA and Asia Pacific regions. Sales of critical care  products remained constant at US$3.4 million in the quarter ended 30  June 2013, compared to US$3,3 million in the previous year's  corresponding quarter. Total revenue, including licensing ......